These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3288573)

  • 1. [Bioequivalence of generic drugs].
    Schwabe U
    Internist (Berl); 1988 Mar; 29(3):147-59. PubMed ID: 3288573
    [No Abstract]   [Full Text] [Related]  

  • 2. Critical therapeutic categories: a contraindication to generic substitution?
    Colaizzi JL; Lowenthal DT
    Clin Ther; 1986; 8(4):370-9. PubMed ID: 3731208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bioequivalence of generic drugs: sense and nonsense].
    Brune K; Dietzel K
    Fortschr Med; 1988 Nov; 106(33):16-7. PubMed ID: 3209169
    [No Abstract]   [Full Text] [Related]  

  • 4. [Generic drugs, bioavailability, and bioequivalence].
    Palma-Aguirre JA
    Gac Med Mex; 1998; 134(4):491-4. PubMed ID: 9789395
    [No Abstract]   [Full Text] [Related]  

  • 5. Genesis of generic drugs.
    Calesnick B; Kreider LA; Dinan A
    Pa Med; 1986 Dec; 89(12):32, 34, 36. PubMed ID: 3808720
    [No Abstract]   [Full Text] [Related]  

  • 6. [Bioequivalence studies of pharmaceutical preparations].
    Vetchý D; Frýbortová K; Rabisková M; Danecková H
    Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comments on the note for guidance on bioavailability and bioequivalence in the European Union.
    Calvo G
    Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():11. PubMed ID: 9800721
    [No Abstract]   [Full Text] [Related]  

  • 8. On testing for bioequivalence.
    Rocke DM
    Biometrics; 1984 Mar; 40(1):225-30. PubMed ID: 6547355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levothyroxine dosage and the limitations of current bioequivalence standards.
    Hennessey JV
    Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):474-5. PubMed ID: 16957756
    [No Abstract]   [Full Text] [Related]  

  • 10. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
    Verbeeck RK; Kanfer I; Walker RB
    Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use].
    Zapater P; Horga JF
    Rev Neurol; 1999 Dec 16-31; 29(12):1235-46. PubMed ID: 10652753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Are therapeutic drugs freely interchangeable? Studies of bioavailability and bioequivalence].
    Blume H
    Verh Dtsch Ges Inn Med; 1988; 94():411-9. PubMed ID: 3061214
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical relevance of the bioavailability/bioequivalence controversy.
    Gottschalk LA
    J Clin Psychiatry; 1986 Sep; 47 Suppl():3-5. PubMed ID: 3528133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview.
    Ereshefsky L; Jann MW; Saklad SR; Davis CM
    J Clin Psychiatry; 1986 Sep; 47 Suppl():6-15. PubMed ID: 3528134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence and narrow therapeutic index drugs.
    Benet LZ; Goyan JE
    Pharmacotherapy; 1995; 15(4):433-40. PubMed ID: 7479195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview on bioavailability and bioequivalence.
    Kaplan SA
    Psychopharmacol Bull; 1976 Oct; 12(4):50-1. PubMed ID: 972989
    [No Abstract]   [Full Text] [Related]  

  • 19. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.